Search Results

GSK plc announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

CoImmune, Inc. today announced the publication of preclinical results with Synthetic Enzyme-Armed Killer (SEAKER) cells in solid tumor melanomas in the peer-reviewed journal Cancer Immunology Research.

GSK plc (LSE/NYSE: GSK) today announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative and equitable approach to helping increase adult immunization rates in the US.

CoImmune, Inc. announced it has exercised its option to obtain an exclusive license in the CD19-targeted, allogeneic cell therapy field to IL-18 Armored Chimeric Antigen Receptor technology under a prior agreement with Memorial Sloan Kettering Cancer Center.

CoImmune, Inc. announced it has exercised its option to obtain an exclusive license in the Delta-like Ligand 3 -targeted, allogeneic Chimeric Antigen Receptor-Cytokine Induced Killer cell therapy field to interleukin-18 Armored CAR technology under a prior agreement with Memorial Sloan Kettering Cancer Center.

CoImmune, Inc. today announced the publication of a review of the company’s clinical development program evaluating CMN-001, a dendritic cell-based immunotherapy electroporated with autologous tumor RNA to treat metastatic renal cell carcinoma (mRCC).

CoImmune, Inc. today announced the publication of preclinical data demonstrating that a strategy based on the company’s proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML).

GSK plc announced the launch of the COiMMUNITY Initiative to help reduce health inequities and set a new precedent for adult immunization rates in the US, which continue to remain below pre-pandemic levelsi.

CoImmune, Inc. today announced that preclinical models show CAR T cells engineered with OrexiCAR technology to secrete a CD47-SIRPα checkpoint blocker have improved anti-tumor activity and reverse myeloid immunosuppression in tumors.

CoImmune, Inc. today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors.